Table 5.
Study Entry Predictors of Fibrosis Regression by at Least 1 Stage: Univariate Analysis
| Factor |
Regression (n = 14) |
No Regressiona (n = 30) |
P Value |
|---|---|---|---|
| Continuous factors | Median (IQR) | Median (IQR) | |
| Duration of cART, years | 12.5 (4.6–13.6) | 11.9 (4.6–13.4) | .533 |
| Duration of HBV-active cART, years | 12.5 (4.6–13.6) | 10.2 (4.6–13.4) | .463 |
| Duration known HIV positive, years | 21.5 (14.0–24.3) | 17.3 (8.3–23.8) | .471 |
| Duration known HCV Ab positive, years | .413 | ||
| HIV RNA, log10 copies/mL | 1.30 (1.30–2.08) | 1.30 (1.3–1.7) | 1.000 |
| HBV DNA, log10 copies/mL | 2.55 (1.30–2.90) | 1.30 (1.30–2.55) | .049 |
| ALT, IU/mL | 42.0 (21.5–63) | 31.0 (17.0–44.3) | .195 |
| Platelets, per µL | 190.0 (160.0–307.0) | 191.0 (133.3–235.0) | .582 |
| Time between 1st and last assessment, months | 31.8 (19.1–48.9) | 32.1 (19.7–40.4) | .791 |
| Categorical factors | % | % | |
| HIV RNA positive | 28.6 | 21.4 | .707 |
| HBV DNA positive | 15.4 | 30.8 | .399 |
| HCV Ab positive | 23.3 | 30.8 | .709 |
Bold text indicates statistically significant result.
Abbreviations: Ab, antibody; ALT, alanine transaminase; cART, combination antiretroviral therapy; DNA, deoxyribonucleic acid; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; RNA, ribonucleic acid.
a No regression defined as no change in fibrosis stage.